A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Status:
Recruiting
Trial end date:
2027-05-23
Target enrollment:
Participant gender:
Summary
Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread
beyond its original location (advanced). In addition, their DDLS either has come back after
treatment (recurrent), has spread to different parts of your body (metastatic), or is unable
to be removed surgically (unresectable). The purpose of this study is to find out whether the
combination of etrumadenant and zimberelimab is an effective treatment for people with
advanced DDLS.